Phase 1CompletedINTERVENTIONAL
A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants
ClinicalTrials.gov · NCT04465396 · Registry updated: 2022-10-04
- Condition / research focus
- Healthy Volunteers
- Sponsor
- Shire
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2021-01-13. Completion: 2021-08-20 (may be estimated). Results are posted in this registry.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Teduglutide (drug) — also listed as: TAK-633
- Syringe Injection (device)
- Pen injector (device)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Celerion
Phoenix, Arizona, United States
Site recruitment: Not reported